For ovarian cancer patients experiencing significant ocular side effects from the ADC mervituximab, switching the dosing schedule from every three weeks to every four weeks can resolve the toxicity by allowing an extra week for recovery.

When choosing between sacituzumab govitecan (SG) and datopotamab deruxtecan (Datto-DXd), oncologists prioritize the differing side effect profiles (diarrhea/neutropenia vs. stomatitis/ocular) and administration schedules (weekly infusions vs. every three weeks) to match patient lifestyle and comorbidities, rather than focusing solely on efficacy.

When choosing between TROP2-directed ADCs like sacituzumab govitecan and datopotamab deruxtecan, the decision often hinges on side effect profiles and scheduling convenience, not superior efficacy. Datopotamab has more oral/ocular issues but is given every three weeks, while sacituzumab causes more neutropenia and requires visits two out of every three weeks.

When treating elderly patients (e.g., age 80+) with metastatic breast cancer, clinicians may prioritize quality of life over marginal overall survival gains seen in clinical trials. This justifies using a better-tolerated CDK4/6 inhibitor like palbociclib, even though ribociclib has demonstrated a statistical survival benefit, especially when patients have comorbidities or a preference for fewer side effects.

Though ADCs like Sacituzumab Govitekan cause notable side effects like diarrhea and neutropenia, patient-reported outcome data shows they provide a meaningful and sustained improvement in quality of life compared to standard chemotherapy. This was observed even with longer treatment durations and lower discontinuation rates.

A unique advantage of the ADC datopotamab deruxtecan is its non-myelosuppressive profile. This makes it an especially attractive option for patients whose bone marrow is compromised or 'tired' after receiving intensive prior chemotherapy, a common real-world clinical scenario not always captured in trials.

When efficacy and safety profiles are comparable between ADCs like sacituzumab and datopotamab, the final choice can be guided by patient logistics. Factors include infusion frequency (Day 1 & 8 vs. every 3 weeks) and total time spent at the infusion center.

For the ADC belantamab mafodotin, clinicians should not feel rigidly bound to the initial every-three-week schedule. Data shows that spreading doses out to every 8 or 12 weeks is a viable strategy, as most patients stabilize or even improve their depth of response despite holding the drug, allowing for better toxicity management.

Clinicians can confidently reduce the dose of Datopotamab-deruxtecan to manage toxicity. Phase 1 data demonstrates a compelling efficacy signal even at a 4 mg/kg dose level, reassuring oncologists that dose reduction is a viable strategy to maintain treatment without sacrificing benefit.